Literature DB >> 2293688

Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use.

P Wølner-Hanssen1, D A Eschenbach, J Paavonen, N Kiviat, C E Stevens, C Critchlow, T DeRouen, K K Holmes.   

Abstract

Studies have shown that oral contraceptive use may protect against pelvic inflammatory disease (PID), but it is not known whether oral contraceptives protect against the disease among women already infected with Chlamydia trachomatis or Neisseria gonorrhoeae. The relationship between oral contraceptive use and PID was analyzed in a case-control study of 141 women with verified PID and 739 randomly selected, sexually active women with no clinical evidence of the disease. Case and control subjects were stratified on the basis of infection with C trachomatis, N gonorrhoeae, or neither organism. Among women infected with C trachomatis alone, those with PID were less likely than control subjects to use oral contraceptives. The association was significant when oral contraceptive use was compared with nonuse (odds ratio, 0.22; 95% confidence interval, 0.08 to 0.64) and with noncontraception (odds ratio, 0.17; 95% confidence interval, 0.06 to 0.53) and remained so after adjusting for potential confounding variables by logistic regression analysis. Among women infected with N gonorrhoeae alone, no association was found between use of oral contraceptives and PID. These data suggest that oral contraceptive use protects against symptomatic PID among women infected with C trachomatis but not among those infected with N gonorrhoeae.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2293688     DOI: 10.1001/jama.1990.03440010052029

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  22 in total

Review 1.  Pelvic inflammatory disease.

Authors:  J Ross
Journal:  BMJ       Date:  2001-03-17

Review 2.  Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?

Authors:  I Simms; J M Stephenson
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

Review 3.  An update on pelvic inflammatory disease.

Authors:  J D C Ross
Journal:  Sex Transm Infect       Date:  2002-02       Impact factor: 3.519

4.  Chlamydia trachomatis and oral contraceptive use: a quantitative review.

Authors:  J Cottingham; D Hunter
Journal:  Genitourin Med       Date:  1992-08

Review 5.  Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions.

Authors:  A M Minnis; N S Padian
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

6.  Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar.

Authors:  F Behets; A Norris Turner; K Van Damme; N L Rabenja; N Ravelomanana; K Zeller; J R Rasolofomanana
Journal:  Sex Transm Infect       Date:  2005-12       Impact factor: 3.519

7.  Discordance between trends in chlamydia notifications and hospital admission rates for chlamydia related diseases in New South Wales, Australia.

Authors:  M Y Chen; C K Fairley; B Donovan
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

Review 8.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2013-12-11

9.  Vaginal microbicide and diaphragm use for sexually transmitted infection prevention: a randomized acceptability and feasibility study among high-risk women in Madagascar.

Authors:  Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson
Journal:  Sex Transm Dis       Date:  2008-09       Impact factor: 2.830

10.  Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam.

Authors:  M Kosseim; A Ronald; F A Plummer; L D'Costa; R C Brunham
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.